A first-in-human phase 1 study of simnotrelvir, a 3CL-like protease inhibitor for treatment of COVID-19, in healthy adult subjects
Authors:
Open Access
- 30 September 2023
- journal article
- research article
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 191, 106598
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Nirmatrelvir Plus Ritonavir: First ApprovalDrugs, 2022
- Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and HumansDrug Metabolism and Disposition, 2022
- An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19Science, 2021
- The Impact of Diet and Exercise on Drug ResponsesInternational Journal of Molecular Sciences, 2021
- On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release TabletPharmaceutics, 2021
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approachBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
- Transporter-Mediated Drug-Drug Interactions and Their Significance2019
- Food effect on meal administration time of pharmacokinetic profile of cilostazol, a BCS class II drugXenobiotica, 2019
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Structure and mechanism of the complex between cytochrome P4503A4 and ritonavirProceedings of the National Academy of Sciences, 2010